These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9720120)

  • 41. The reliability and validity of general psychotic rating scales with people with mild and moderate intellectual disabilities: an empirical investigation.
    Hatton C; Haddock G; Taylor JL; Coldwell J; Crossley R; Peckham N
    J Intellect Disabil Res; 2005 Jul; 49(Pt 7):490-500. PubMed ID: 15966956
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The PANSS (Positive And Negative Symptom) Scale].
    Guelfi JD
    Encephale; 1997 Apr; 23 Spec No 2():35-8. PubMed ID: 9273305
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Symptom structure and severity: a comparison of responses to the positive and negative syndrome scale (PANSS) between patients with PTSD or schizophrenia.
    Stefanovics EA; Krystal JH; Rosenheck RA
    Compr Psychiatry; 2014 May; 55(4):887-95. PubMed ID: 24602497
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sustained and "sleeper" effects of group metacognitive training for schizophrenia: a randomized clinical trial.
    Moritz S; Veckenstedt R; Andreou C; Bohn F; Hottenrott B; Leighton L; Köther U; Woodward TS; Treszl A; Menon M; Schneider BC; Pfueller U; Roesch-Ely D
    JAMA Psychiatry; 2014 Oct; 71(10):1103-11. PubMed ID: 25103718
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PANSS-6: a brief rating scale for the measurement of severity in schizophrenia.
    Østergaard SD; Lemming OM; Mors O; Correll CU; Bech P
    Acta Psychiatr Scand; 2016 Jun; 133(6):436-44. PubMed ID: 26558537
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia.
    Peralta V; Cuesta MJ
    Psychiatry Res; 1994 Jul; 53(1):31-40. PubMed ID: 7991730
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
    Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
    J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An excitement subscale of the Positive and Negative Syndrome Scale.
    Lindenmayer JP; Brown E; Baker RW; Schuh LM; Shao L; Tohen M; Ahmed S; Stauffer VL
    Schizophr Res; 2004 Jun; 68(2-3):331-7. PubMed ID: 15099614
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Complementary group Metacognitive Training (MCT) reduces delusional ideation in schizophrenia.
    Moritz S; Veckenstedt R; Bohn F; Hottenrott B; Scheu F; Randjbar S; Aghotor J; Köther U; Woodward TS; Treszl A; Andreou C; Pfueller U; Roesch-Ely D
    Schizophr Res; 2013 Dec; 151(1-3):61-9. PubMed ID: 24183707
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anhedonia and negative symptomatology in chronic schizophrenia.
    Loas G; Boyer P; Legrand A
    Compr Psychiatry; 1996; 37(1):5-11. PubMed ID: 8770519
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Obtaining employment as an anchor for estimating the minimum clinically important difference on the Positive and Negative Syndrome Scale (PANSS) in schizophrenia.
    Leddy-Stacy MA; Rosenheck R
    Psychiatry Res; 2016 Apr; 238():304-309. PubMed ID: 27086249
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia.
    Davidson M; Saoud J; Staner C; Noel N; Luthringer E; Werner S; Reilly J; Schaffhauser JY; Rabinowitz J; Weiser M; Luthringer R
    Am J Psychiatry; 2017 Dec; 174(12):1195-1202. PubMed ID: 28750582
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia.
    Harvey RC; James AC; Shields GE
    CNS Drugs; 2016 Jan; 30(1):27-39. PubMed ID: 26801655
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Validation of the Spanish version of the Clinical Assessment for Negative Symptoms (CAINS).
    Valiente-Gómez A; Mezquida G; Romaguera A; Vilardebò I; Andrés H; Granados B; Larrubia J; Pomarol-Clotet E; McKenna PJ; Sarró S; Bernardo M
    Schizophr Res; 2015 Aug; 166(1-3):104-9. PubMed ID: 26116328
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
    Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
    JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Validity and reliability of the French-language version of the Positive and Negative Syndrome Scale (PANSS).
    Lançon C; Reine G; Llorca PM; Auquier P
    Acta Psychiatr Scand; 1999 Sep; 100(3):237-43. PubMed ID: 10493091
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sensitivity of individual items of the Positive and Negative Syndrome Scale (PANSS) and items subgroups to differentiate between placebo and drug treatment in schizophrenia.
    Kozielska M; Pilla Reddy V; Johnson M; de Ridder F; Vermeulen A; Liu J; Groothuis GM; Danhof M; Proost JH
    Schizophr Res; 2013 May; 146(1-3):53-8. PubMed ID: 23434198
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
    Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
    J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of the use of the positive and negative syndrome scale-excited component as a criterion for administration of p.r.n. medication.
    Chaichan W
    J Psychiatr Pract; 2008 Mar; 14(2):105-13. PubMed ID: 18360196
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Core factors of schizophrenia structure based on PANSS and SAPS/SANS results. Discerning and head-to-head comparisson of PANSS and SASPS/SANS validity].
    Masiak M; Loza B
    Psychiatr Pol; 2004; 38(5):795-808. PubMed ID: 15523927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.